Table 1.
Clinical studies with homoharringtonine and omacetaxine in patients with CML (focus on chronic phase).
| Setting / Study | Drug | Regimen | No. | Major cytogenetic response rate | Reference |
|---|---|---|---|---|---|
| Post interferon therapy | |||||
| O'Brien | HHT | Single agent | 71 | 15 | 21 |
| Kantarjian | HHT | With LDAC | 100 | 15 | 23 |
| First-line therapy | |||||
| O'Brien | HHT | Single agent | 90 | 27 | 22 |
| O'Brien | HHT | With IFN | 37 | 43 | 22 |
| Ernst | HHT | With LDAC | 14 | 84 | In 23 |
| Stone | HHT | With LDAC | 44 | 17 | 24 |
| O'Brien | HHT | With LDAC and IFN | 90 | 46 | 25 |
| Post TKI therapy | |||||
| Cortes (T315I) | Omace | Single agent | 62 | 23 | 1 |
| Cortes (≥2 TKI) | Omace | Single agent | 46 | 22 | 2 |
| Cortes (≥2 TKI) | Omace | Single agent | 81 | 20 | 3 |
| Marin (MCyR on imatinib) | SS HHT | With imatinib | 10 | NA | 27 |
NA = not applicable; patients entered the study with MCyR. The objective was to achieve an improvement in transcript levels. Thus was achieved in 7 of 10 patients.
Omace = Omacetaxine; SS HHT = Semisynthetic HHT; LDAC = low-dose cytarabine; IFN = interferon